Skip to main content

Drug Interactions between dabrafenib and Tyvaso

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

treprostinil dabrafenib

Applies to: Tyvaso (treprostinil) and dabrafenib

MONITOR: Coadministration with inducers of CYP450 2C8 may decrease the plasma concentrations of treprostinil, which is primarily metabolized by the isoenzyme. Human pharmacokinetic studies with an oral formulation of treprostinil indicate that concomitant administration of the CYP450 2C8 inducer rifampin decreases exposure (both Cmax and AUC) to treprostinil. However, it has not been determined if the safety and efficacy of treprostinil administered subcutaneously or intravenously are altered by this interaction.

MANAGEMENT: Pharmacologic response to treprostinil should be monitored more closely whenever a CYP450 2C8 inducer is added to or withdrawn from therapy, and the treprostinil dosage adjusted as necessary. Patients should be advised to notify their physician if they experience worsening of their condition.

References

  1. (2002) "Product Information. Remodulin (treprostinil)." United Therapeutics Corporation
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  3. Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
  4. Cerner Multum, Inc. (2015) "Canadian Product Information."
View all 4 references

Switch to consumer interaction data

Drug and food interactions

Moderate

dabrafenib food

Applies to: dabrafenib

ADJUST DOSING INTERVAL: Food may reduce as well as delay the absorption of dabrafenib. In study subjects, administration of dabrafenib with a high-fat meal decreased peak plasma concentration (Cmax) and systemic exposure (AUC) by 51% and 31%, respectively, and delayed median Tmax by approximately 3.6 hours compared to administration in the fasted state.

MANAGEMENT: Dabrafenib should be taken at least 1 hour before or 2 hours after a meal.

References

  1. (2013) "Product Information. Tafinlar (dabrafenib)." GlaxoSmithKline

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer